Your browser doesn't support javascript.
loading
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.
O'Sullivan Coyne, Geraldine; Kummar, Shivaani; Hu, James; Ganjoo, Kristen; Chow, Warren A; Do, Khanh T; Zlott, Jennifer; Bruns, Ashley; Rubinstein, Lawrence; Foster, Jared C; Juwara, Lamin; Meehan, Robert; Piekarz, Richard; Streicher, Howard; Sharon, Elad; Takebe, Naoko; Voth, Andrea Regier; Bottaro, Donald; Costello, Rene; Wright, John J; Doroshow, James H; Chen, Alice P.
Afiliación
  • O'Sullivan Coyne G; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Kummar S; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Hu J; University of Southern California, Los Angeles, California.
  • Ganjoo K; Stanford Cancer Center, Stanford University, Palo Alto, California.
  • Chow WA; City of Hope Medical Center, Duarte, California.
  • Do KT; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Zlott J; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Bruns A; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Rubinstein L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Foster JC; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Juwara L; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Meehan R; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Piekarz R; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Takebe N; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Voth AR; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Bottaro D; Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Costello R; Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Wright JJ; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
  • Doroshow JH; Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Chen AP; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.
Clin Cancer Res ; 28(2): 279-288, 2022 01 15.
Article en En | MEDLINE | ID: mdl-34716194
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Factor A de Crecimiento Endotelial Vascular Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Factor A de Crecimiento Endotelial Vascular Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos